Skip to main content

Interpretation Training Program for Non-small Cell Lung Cancer (NSCLC): PD-L1 IHC 22C3 pharmDx (SK006)

Are you ready to assess PD-L1 expression in NSCLC?

PD-L1 testing provides a direct assessment of PD-L1 expression, which is a biomarker for response to anti-PD-1 therapy in NSCLC. Get educated on how to evaluate and score PD-L1 expression in NSCLC using PD-L1 IHC 22C3 pharmDx.

The PD-L1 IHC 22C3 pharmDx NSCLC Interpretation Training Program provides education that may help you accurately evaluate and score PD-L1 expression in patients with NSCLC

The PD-L1 IHC 22C3 pharmDx Interpretation Training Program uses in-depth content, engaging activities, and comprehensive cases to help you confidently:
  • Understand the core principles of PD-L1 pathology
  • Learn the process for evaluating stained specimens for PD-L1 expression
  • Recognize important considerations that affect PD-L1 scoring
  • Score specimens for PD-L1 expression across a variety of patient samples

1. PD-L1 IHC 22C3 pharmDx [Instructions for Use]. Santa Clara, CA: Agilent Technologies, Inc.; 2021.

2. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. See the KEYTRUDA product label for PD-L1 expression cutoff values and specific clinical circumstances guiding therapy.

3. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-1550.

4. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-1833.

5. LIBTAYO is a registered trademark of Regeneron Pharmaceuticals, Inc. See the LIBTAYO product label for specific clinical circumstances guiding therapy.

6. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592-604.

D67464/01 2021AUG04

Review the PD-L1 IHC 22C3 pharmDx Intended Use